Treatment outcomes for acute T-lymphoblastic leukemias/lymphomas: data from the ALL-2016 multicenter prospective randomized trial

Background. The effectiveness of therapy for acute T-lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL) has significantly improved over the past decades, including through the implementation of hematopoietic stem cell transplantation (HSCT). The Russian multicenter ALL-2009 study (ClinicalTrials.gov NCT01193933) showed that performing autologous HSCT (auto-HSCT) in patients with T-ALL/LBL improves long-term results. However, the study was non-randomized and the need for auto-HSCT in clinical practice requires careful study.
Aim. To assess the significance of auto-HSCT in patients with T-ALL/LBL in the framework of ALL-2016 multicenter, prospective, randomized study (ClinicalTrials.gov NCT03462095).
Materials and methods. The study included 109 adult patients with T-ALL/LBL (m:f 82:27). Median age was 31 (18– 52) years. T-ALL was diagnosed in 88 (81 %) patients, T-LBL in 21 (19 %) patients. All patients are treated according to the ALL-2016 protocol. Using the web platform, upon completion of induction therapy (+70 days), all T-ALL/LBL patients who achieved clinical and hematological remission were randomized to the auto-HSCT arm or chemotherapy alone (CT). Centralized monitoring of minimal residual disease (MRD) in bone marrow samples was performed by multicolor flow cytometry at the control points according to the ALL-2016 protocol. Statistical analysis was performed using SAS 9.4.
Results. 87 patients with T-ALL/LBL were randomized: 44 to the auto-HSCT arm and 43 to the CT arm. Further analysis included 25 patients who underwent auto-HSCT and 36 patients receiving only CT. Three-year relapse-free survival in T-ALL is estimated at 62 % (auto-HSCT) vs. 81 % (CT) (p = 0.3422), and in T-LBL – 67 % (auto-HSCT) vs. 79 % (CT) (p = 0.59). MRD persistence on the +70^th day of therapy according to the ALL-2016 protocol was determined in 40 % of patients (autoHSCT) and in 67 % (CT) (p = 0.057). In a multivariate analysis, it was determined that T-ALL from early T-cell precursor (ETP-variant) and MRD persistence after the end of II phase induction are the main risk factors for relapse in the treatment according to the ALL-2016 protocol.
Conclusion. Performing auto-HSCT both in patients with T-ALL and T-LBL, and with MRD persistence on day +70 according to the ALL-2016 protocol did not improve long-term results. The development of new programs for the treatment of patients with MRD persistence, as well as the ETP variant of T-ALL, is of current interest.

1. Swerdlow S.H., Campo E., Harris N.L. et al. WHO classification of tumours of haemotopoietic and lymphoid tissues. Lyon: IARC, 2008. P. 586.

2. Swerdlow S.H., Campo E., Harris N.L. et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th edn. Lyon: IARC, 2017. P. 585.

3. Arber D.A., Orazi A., Hasserjian R.P. et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022;140(11):1200–28. DOI:10.1182/blood.2022015850

4. Shervashidze M.A., Valiev T.T. Pediatric acute lymphoblastic leukemia treatment protocols improvement: emphasis on minimal residual disease. Onkogematologiya = Oncohematology 2020;15(3): 12–26. (In Russ.). DOI:10.17650/1818-8346-2020-15-3-12-26

5. Dhédin N., Dombret H., Thomas X. et al. Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials. Leukemia 2006;20(2):336–44. DOI:10.1038/sj.leu.2404065

6. Hoelzer D., Thiel E., Arnold R. et al. Successful subtype oriented treatment strategies in adult T-All; results of 744 patients treated in three consecutive GMALL studies. Blood 2009;114:324.

7. Arnold R., Terwey T.H., Vuong G.L. et al. Allogeneic stem cell transplantation in adults with high risk acute lymphoblastic leukemia (ALL) in first remission (CR1): promising, but strongly influenced by ALL subtypes. Blood 2013;122(21):3409. DOI:10.1182/blood.V122.21.3409.3409

8. Marks D.I., Paietta E.M., Moorman A.V. et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood 2009;114(25):5136–45. DOI:10.1182/blood-2009-08-231217

9. Dhédin N., Huynh A., Maury S. et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood 2015;125(16):2486–96; quiz 2586. DOI:10.1182/blood-2014-09-599894

10. Parovichnikova E.N., Sokolov A.N., Troitskaya V.V. et al. Acute Ph-negative lymphoblastic leukemias in adults: risk factors in the use of the ALL-2009 protocol. Terapevticheskii arkhiv = Therapeutic Archive 2016;88(7):15–24. (In Russ.). DOI:10.17116/terarkh201688715-24

11. Semochkin S.V., Tolstykh T.N., Arkhipova N.V. et al. Clinical and epidemiological characteristics of acute myeloid leukemias in adults according to the data of the municipal hematology departments of Moscow. Terapevticheskii arkhiv = Therapeutic Archive 2015;87(7):26–32. (In Russ.). DOI:10.17116/terarkh201587726-32

12. Goldstone A.H., Richards S.M., Lazarus H.M. et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008;111(4): 1827–33. DOI:10.1182/blood-2007-10-116582

13. Ribera J.M., Oriol A., Bethencourt C. et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica 2005;90(10):1346–56.

14. Hunault M., Harousseau J.L., Delain M. et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late highdose therapy and autologous BMT: a GOELAMS trial. Blood 2004;104(10):3028–37. DOI:10.1182/blood-2003-10-3560

15. Cornelissen J.J., Van Der Holt B., Verhoef G.E.G. et al. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: A prospective sibling donor versus no-donor comparison. Blood 2009;113(6):1375–82. DOI:10.1182/blood-2008-07-168625

16. Algorithms for diagnosis and protocols for the treatment of the blood system diseases. Ed.: V.G. Savchenko. Мoscow: Praktika, 2018. Pp. 571–619, 887–959. (In Russ.).

17. Rumyantseva Yu.V., Karachunsky A.I., Rumyantsev A.G. Optimization of therapy for acute lymphoblastic leukemia in children in Russia. Pediatriya = Pediatrics 2009;87(4):19–27. (In Russ.).

18. Aleskerova G.A., Shervashidze M.A., Popa A.V. et al. Treatment results of ALL IC-BFM 2002 protocol in children with acute lymphoblastic leukemia. Onkopediatriya = Oncopediatrics 2016;3(4):302–8. (In Russ.).

19. Parovichnikova E., Troitskaya V., Sokolov A. et al. Can less intensive chemotherapy and an autotransplant cure adult T-cell acute lymphoblastic leukemia? Acta Haematol 2020;143(2):131–9. DOI:10.1159/000502435

20. Parovichnikova E.N., Gavrilina O.A., Troitskaya V.V. et al. Protocol of a multicenter study on the treatment of Ph-negative adult acute lymphoblastic leukemia (ALL) with a randomization stage for T-cell ALL/lymphomas “ALL-2016”. Ed.: V.G. Savchenko. Moscow: Praktika, 2018. Pp. 887–959. (In Russ.).

21. Gokbuget N., Bassan R., Dombret H. et al. Recommendations of the European Working Group for Adult ALL. UNIMED Ve. Bremen–London–Boston, 2011.

22. Galtseva I.V., Davydova Yu.O., Parovichnikova E.N. Detection of measurable residual disease in adults li with acute leukaemia. Gematologiya i transfuziologiya = Hematology and Transfusiology 2020;65(4):460–72. (In Russ.). DOI:10.35754/0234-5730-202065-4-460-472